In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Skyrizi (AbbVie)
- INDICATIONS: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- CLASS: Interleukin-23 inhibitor, Monoclonal antibody
- HALF-LIFE: ~ 28 days
- FDA APPROVAL DATE: 04/23/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines - PREGNANCY: Limited available data in pregnant women to evaluate a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Risankizumab may be transmitted from the mother to the developing fetus.
- See adverse reactions attributed to class:
May increase the risk of infection. Evaluate for TB prior to initiating treatment with risankizumab.
Risankizumab-Rzaa is a biosimilar to Risankizumab.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of risankizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/30/2024
